Washington, DC (Sept 9, 2011) -- The blood levels of a particular hormone can help predict which kidney disease patients will develop heart problems, need dialysis, and die prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). Testing for this hormone could identify which patients need early treatment, thereby lowering their health risks and lengthening their lives.
In patients with chronic kidney disease (CKD), blood levels of a hormone called fibroblast growth factor-23 (FGF-23) rise in parallel with declining kidney function. Researchers have wondered whether FGF-23 levels might also predict which CKD patients will develop heart problems (the number one killer of CKD patients), need dialysis, or die prematurely.
To find out, Jessica Kendrick, MD, Michel Chonchol, MD (University of Colorado), and their colleagues measured FGF-23 levels in the blood of 1,099 patients with advanced CKD, dividing patients into four groups or quartiles based on their FGF-23 levels. After following patients for an average of 2.9 years, the researchers found that more patients in the groups with higher FGF-23 levels developed heart problems, needed dialysis, and died than those with lower levels of the hormone. Specifically, compared with the group with the lowest levels of FGF-23, each subsequent quartile had a progressively higher risk of dying during the study. The two highest quartiles had significantly elevated risks for developing heart problems and needing dialysis.
The findings suggest that blood levels of FGF-23 might be used to guide therapies in patients with CKD. "FGF-23 may be a modifiable risk factor in patients with CKD as it strongly associated with the most important outcomes encountered by these patients: death, cardiovascular events, and initiation of dialysis," said Dr. Chonchol. Additional studies are needed to determine whether treatments to lower FGF-23 levels benefit CKD patients.
Study co-authors include Alfred Cheung, MD, Tom Greene, PhD (Veterans Affairs Salt Lake City Healthcare System and University of Utah, Salt Lake City); James Kaufman, MD (Veterans Affairs Boston Healthcare System and Boston University School of Medicine); William Roberts, MD, PhD (University of Utah, Salt Lake City); Gerard Smits, PhD (University of Colorado Denver); and the HOST Investigators.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Elevated FGF-23 Associates with Death, Cardiovascular Events and Dialysis Initiation," will appear online at http://jasn.asnjournals.org/ doi 10.1681/ASN.2010121224
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
Journal
Journal of the American Society of Nephrology